Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Hormone Refractory Breast Cancer market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Hormone Refractory Breast Cancermarket, defines the market attractiveness level of Hormone Refractory Breast Cancer market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Hormone Refractory Breast Cancer industry, describes the types of Hormone Refractory Breast Cancer market, the applications of major players and the market size, and deeply analyzes the current situation of the global Hormone Refractory Breast Cancer market and the development prospects and opportunities of Hormone Refractory Breast Cancer industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Hormone Refractory Breast Cancer market in Chapter 13.
By Player:
Neopharm
AmpliMed Corporation
NeoCorp
Sanof Genzyme
Boehringer IngelheimGmbH
Roche
AstraZeneca
Bluefish Pharmaceuticals AB
By Type:
Tumor Markers Therapy
Gene Expression Therapy
Gene Mutation Therapy
By End-User:
Scientific Research and Production
Biological Science and Technology
Medical Technology
Medical Apparatus and Instruments
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Hormone Refractory Breast Cancer Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Hormone Refractory Breast Cancer Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Hormone Refractory Breast Cancer Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Hormone Refractory Breast Cancer Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Hormone Refractory Breast Cancer Market Analysis and Outlook to 2022
-
7.1 Global Hormone Refractory Breast Cancer Consumption (2017-2022)
-
7.2 United States Hormone Refractory Breast Cancer Consumption (2017-2022)
-
7.3 Europe Hormone Refractory Breast Cancer Consumption (2017-2022)
-
7.4 China Hormone Refractory Breast Cancer Consumption (2017-2022)
-
7.5 Japan Hormone Refractory Breast Cancer Consumption (2017-2022)
-
7.6 India Hormone Refractory Breast Cancer Consumption (2017-2022)
-
7.7 South Korea Hormone Refractory Breast Cancer Consumption (2017-2022)
8 Region and Country-wise Hormone Refractory Breast Cancer Market Analysis and Outlook to 2028
-
8.1 Global Hormone Refractory Breast Cancer Consumption Forecast (2022-2028)
-
8.2 United States Hormone Refractory Breast Cancer Consumption Forecast (2022-2028)
-
8.3 Europe Hormone Refractory Breast Cancer Consumption Forecast (2022-2028)
-
8.4 China Hormone Refractory Breast Cancer Consumption Forecast (2022-2028)
-
8.5 Japan Hormone Refractory Breast Cancer Consumption Forecast (2022-2028)
-
8.6 India Hormone Refractory Breast Cancer Consumption Forecast (2022-2028)
-
8.7 South Korea Hormone Refractory Breast Cancer Consumption Forecast (2022-2028)
9 Global Hormone Refractory Breast Cancer Market Outlook by Types and Applications to 2022
-
9.1 Global Hormone Refractory Breast Cancer Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Tumor Markers Therapy Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Gene Expression Therapy Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Gene Mutation Therapy Consumption and Growth Rate (2017-2022)
-
9.2 Global Hormone Refractory Breast Cancer Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Scientific Research and Production Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Biological Science and Technology Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Medical Technology Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Medical Apparatus and Instruments Consumption and Growth Rate (2017-2022)
10 Global Hormone Refractory Breast Cancer Market Outlook by Types and Applications to 2028
-
10.1 Global Hormone Refractory Breast Cancer Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Tumor Markers Therapy Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Gene Expression Therapy Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Gene Mutation Therapy Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Hormone Refractory Breast Cancer Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Scientific Research and Production Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Biological Science and Technology Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Medical Technology Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Medical Apparatus and Instruments Consumption Forecast and Growth Rate (2022-2028)
11 Global Hormone Refractory Breast Cancer Import and Export Analysis (Top 5 Countries)
-
11.1 Global Hormone Refractory Breast Cancer Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Hormone Refractory Breast Cancer Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Hormone Refractory Breast Cancer Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Hormone Refractory Breast Cancer Market Competitive Analysis
-
14.1 Neopharm
-
14.1.1 Neopharm Company Details
-
14.1.2 Neopharm Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Neopharm Hormone Refractory Breast Cancer Product and Service
-
14.2 AmpliMed Corporation
-
14.2.1 AmpliMed Corporation Company Details
-
14.2.2 AmpliMed Corporation Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 AmpliMed Corporation Hormone Refractory Breast Cancer Product and Service
-
14.3 NeoCorp
-
14.3.1 NeoCorp Company Details
-
14.3.2 NeoCorp Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 NeoCorp Hormone Refractory Breast Cancer Product and Service
-
14.4 Sanof Genzyme
-
14.4.1 Sanof Genzyme Company Details
-
14.4.2 Sanof Genzyme Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Sanof Genzyme Hormone Refractory Breast Cancer Product and Service
-
14.5 Boehringer IngelheimGmbH
-
14.5.1 Boehringer IngelheimGmbH Company Details
-
14.5.2 Boehringer IngelheimGmbH Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Boehringer IngelheimGmbH Hormone Refractory Breast Cancer Product and Service
-
14.6 Roche
-
14.6.1 Roche Company Details
-
14.6.2 Roche Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Roche Hormone Refractory Breast Cancer Product and Service
-
14.7 AstraZeneca
-
14.7.1 AstraZeneca Company Details
-
14.7.2 AstraZeneca Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 AstraZeneca Hormone Refractory Breast Cancer Product and Service
-
14.8 Bluefish Pharmaceuticals AB
-
14.8.1 Bluefish Pharmaceuticals AB Company Details
-
14.8.2 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Hormone Refractory Breast Cancer
-
Figure Hormone Refractory Breast Cancer Picture
-
Table Global Hormone Refractory Breast Cancer Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Hormone Refractory Breast Cancer Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Hormone Refractory Breast Cancer Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Hormone Refractory Breast Cancer Consumption by Country (2017-2022)
-
Figure United States Hormone Refractory Breast Cancer Consumption and Growth Rate (2017-2022)
-
Table Europe Hormone Refractory Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure China Hormone Refractory Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Japan Hormone Refractory Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure India Hormone Refractory Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure South Korea Hormone Refractory Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Hormone Refractory Breast Cancer Consumption Forecast by Country (2022-2028)
-
Figure United States Hormone Refractory Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Hormone Refractory Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Hormone Refractory Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Hormone Refractory Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Hormone Refractory Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Hormone Refractory Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Tumor Markers Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Gene Expression Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Gene Mutation Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Scientific Research and Production Consumption and Growth Rate (2017-2022)
-
Figure Global Biological Science and Technology Consumption and Growth Rate (2017-2022)
-
Figure Global Medical Technology Consumption and Growth Rate (2017-2022)
-
Figure Global Medical Apparatus and Instruments Consumption and Growth Rate (2017-2022)
-
Figure Global Tumor Markers Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Gene Expression Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Gene Mutation Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Scientific Research and Production Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Biological Science and Technology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Medical Technology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Medical Apparatus and Instruments Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Hormone Refractory Breast Cancer Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Hormone Refractory Breast Cancer Export by Region (Top 5 Countries) (2017-2028)
-
Table Neopharm (Foundation Year, Company Profile and etc.)
-
Table Neopharm Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Neopharm Hormone Refractory Breast Cancer Product and Service
-
Table AmpliMed Corporation (Foundation Year, Company Profile and etc.)
-
Table AmpliMed Corporation Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table AmpliMed Corporation Hormone Refractory Breast Cancer Product and Service
-
Table NeoCorp (Foundation Year, Company Profile and etc.)
-
Table NeoCorp Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table NeoCorp Hormone Refractory Breast Cancer Product and Service
-
Table Sanof Genzyme (Foundation Year, Company Profile and etc.)
-
Table Sanof Genzyme Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanof Genzyme Hormone Refractory Breast Cancer Product and Service
-
Table Boehringer IngelheimGmbH (Foundation Year, Company Profile and etc.)
-
Table Boehringer IngelheimGmbH Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer IngelheimGmbH Hormone Refractory Breast Cancer Product and Service
-
Table Roche (Foundation Year, Company Profile and etc.)
-
Table Roche Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Hormone Refractory Breast Cancer Product and Service
-
Table AstraZeneca (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Hormone Refractory Breast Cancer Product and Service
-
Table Bluefish Pharmaceuticals AB (Foundation Year, Company Profile and etc.)
-
Table Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Product and Service
-
